What are the symptoms of resistance to dacomitinib?

Dacomitinib (Dacomitinib), as a second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), has demonstrated excellent clinical efficacy in the treatment of lung cancer, especially in the treatment of EGFR mutant non-small cell lung cancer (NSCLC). It effectively inhibits the growth and spread of tumor cells by precisely binding to EGFR and blocking its signaling pathway, providing patients with new treatment hope.

However, as treatment progresses, some patients may face the problem of resistance to dacomitinib. The emergence of drug resistance often means that tumor cells have found a mechanism to bypass the inhibitory effect of drugs, resulting in weakened or ineffective drug efficacy. The manifestations of dacomitinib resistance are diverse, but are usually related to tumor recurrence, metastasis, or disease progression. Patients may reappear or worsen original lung cancer symptoms, such as cough, difficulty breathing, chest pain, etc. In addition, imaging examinations may also show an increase in tumor lesions or the emergence of metastases. More importantly, genetic testing can detect the emergence or abnormality of corresponding drug resistance genes. These drug resistance genes may be the root cause of dacomitinib failure.

In the case of dacomitinib resistance, doctors will develop a personalized treatment plan based on the patient's specific situation. A common strategy is to perform genetic testing again to clarify the type of resistance genes and select appropriate second- or third-line treatments based on the test results. For example, for dacomitinib resistance caused by the EGFR T790M mutation, third-generation EGFR-TKIs such as osimertinib may be an effective treatment option. In addition, the combined application of immunotherapy drugs is also considered a possible strategy to enhance tumor control and elimination by activating the patient's own immune system.

In summary, dacomitinib, as a highly effective targeted therapy for lung cancer, has brought new treatment options to EGFR mutant NSCLC patients. However, the emergence of drug resistance is an inevitable challenge. Through timely disease monitoring, genetic testing and reasonable treatment adjustments, we can effectively deal with the problems caused by dacomitinib resistance, prolong the survival period of patients and improve the quality of life.